Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Revolution Medicines (RVMD) Income from Continuing Operations (2019 - 2025)

Revolution Medicines has reported Income from Continuing Operations over the past 7 years, most recently at 364892000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 364892000.0 for Q4 2025, down 189.99% from a year ago — trailing twelve months through Dec 2025 was 1131301000.0 (down 3232188.57% YoY), and the annual figure for FY2025 was 1131301000.0, down 3232188.57%.
  • Income from Continuing Operations for Q4 2025 was 364892000.0 at Revolution Medicines, down from 305206000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for RVMD hit a ceiling of 405489000.0 in Q4 2024 and a floor of 364892000.0 in Q4 2025.
  • Median Income from Continuing Operations over the past 5 years was 85813500.0 (2022), compared with a mean of 100388350.0.
  • Biggest five-year swings in Income from Continuing Operations: crashed 190.52% in 2023 and later soared 345.18% in 2024.
  • Revolution Medicines' Income from Continuing Operations stood at 52676000.0 in 2021, then decreased by 8.07% to 56927000.0 in 2022, then tumbled by 190.52% to 165385000.0 in 2023, then soared by 345.18% to 405489000.0 in 2024, then crashed by 189.99% to 364892000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 364892000.0 (Q4 2025), 305206000.0 (Q3 2025), and 247787000.0 (Q2 2025) per Business Quant data.